Michael Moshman

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

Patheon, Inc. provides drug development and manufacturing services to global pharmaceutical, biotechnology and specialty pharmaceutical companies. It operates through two segments: Commercial Manufacturing Outsourcing and Pharmaceutical Development Services. The Commercial Manufacturing Outsourcing segment manufactures prescription products in sterile dosage forms as well as solid and liquid conventional dosage forms. The Pharmaceutical Development Services segment provides a broad range of development services, including solid and sterile dosage forms. The company operates through four market segments: Biologics, Emerging Pharma, Generics and Large Pharma. Patheon was founded in 1974 and is headquartered in Mississauga, Canada.

Part of Septodont Ou Septodont SAS Ou Specialites Septodont, Novocol Pharmaceutical of Canada, Inc. manufactures dental anesthetics. Novocol Pharmaceutical of Canada was acquired by Deproco, Inc. from Henry Schein, Inc. on October 23, 2000.